FDA Approves Zevaskyn for Rare, Genetic Skin Disorder

TUESDAY, April 29, 2025-- The U.S. Food and Drug Administration has approved Zevaskyn (prademagene zamikeracel) for patients with the rare, genetic skin disorder recessive dystrophic epidermolysis bullosa.Zevaskyn is the first and only autologous...